Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q15067
UPID:
ACOX1_HUMAN
Alternative names:
Palmitoyl-CoA oxidase; Peroxisomal fatty acyl-CoA oxidase; Straight-chain acyl-CoA oxidase
Alternative UPACC:
Q15067; A8K6X8; A8KAA0; B4DK61; F5GYQ8; Q12863; Q15068; Q15101; Q16131; Q7Z3W5; Q9UD31
Background:
Peroxisomal acyl-coenzyme A oxidase 1, also known as Palmitoyl-CoA oxidase, plays a pivotal role in the beta-oxidation of very-long-chain fatty acids. This enzyme catalyzes the desaturation of fatty acyl-CoAs, converting them into enoyl-CoAs and producing hydrogen peroxide. Its activity is crucial for energy production and lipid metabolism, with optimal activity against medium-chain fatty acyl-CoAs.
Therapeutic significance:
The enzyme's dysfunction is linked to Adrenoleukodystrophy, pseudoneonatal, and Mitchell syndrome, diseases characterized by neurological and metabolic abnormalities. Understanding the role of Peroxisomal acyl-coenzyme A oxidase 1 could open doors to potential therapeutic strategies for these disorders, highlighting its importance in medical research.